Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

Risa Haruki; Takuya Kimura; Hitomi Iwasaki; Kana Yamada; Ikuo Kamiyama; Mitsutomo Kohno; Kazuaki Taguchi; Saori Nagao; Toru Maruyama; Masaki Otagiri; Teruyuki Komatsu

doi:10.1038/srep12778

Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

Risa Haruki, Takuya Kimura, Hitomi Iwasaki, Kana Yamada, Ikuo Kamiyama, Mitsutomo Kohno, Kazuaki Taguchi, Saori Nagao, Toru Maruyama, Masaki Otagiri, Teruyuki Komatsu

外科学

研究成果: Article › 査読

34 被引用数 (Scopus)

抄録

A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

本文言語	English
論文番号	12778
ジャーナル	Scientific reports
巻	5
DOI	https://doi.org/10.1038/srep12778
出版ステータス	Published - 2015 7月 29

ASJC Scopus subject areas

一般

文献へのアクセス

10.1038/srep12778

他のファイルとリンク

引用スタイル

@article{877ca1bc4fcc4108b6cf227c37265027,

title = "Safety Evaluation of Hemoglobin-Albumin Cluster {"}HemoAct{"} as a Red Blood Cell Substitute",

abstract = "A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as {"}HemoAct{"}, is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.",

author = "Risa Haruki and Takuya Kimura and Hitomi Iwasaki and Kana Yamada and Ikuo Kamiyama and Mitsutomo Kohno and Kazuaki Taguchi and Saori Nagao and Toru Maruyama and Masaki Otagiri and Teruyuki Komatsu",

note = "Funding Information: This work was supported by a Grant-in-Aid for Scientific Research on Innovative Area (“Coordination Programming” Area 2107, No. 21108013) from MEXT Japan, and by a Joint Research Grant from the Institute of Science and Engineering, Chuo University. The authors acknowledge Mr. Katsunori Maejima, Chuo University, for skillful experiments related to Hb purification, Dr. Keitaro Sou, Waseda University, for his kind support on viscosity measurements, Dr. Yuichiro Hayashi, Keio University, for valuable comments related to histopathologic observations, and the members of the Radioisotope Center, Kumamoto University, for important contributions to pharmacokinetic experiments.",

year = "2015",

month = jul,

day = "29",

doi = "10.1038/srep12778",

language = "English",

volume = "5",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

AU - Haruki, Risa

AU - Kimura, Takuya

AU - Iwasaki, Hitomi

AU - Yamada, Kana

AU - Kamiyama, Ikuo

AU - Kohno, Mitsutomo

AU - Taguchi, Kazuaki

AU - Nagao, Saori

AU - Maruyama, Toru

AU - Otagiri, Masaki

AU - Komatsu, Teruyuki

N1 - Funding Information: This work was supported by a Grant-in-Aid for Scientific Research on Innovative Area (“Coordination Programming” Area 2107, No. 21108013) from MEXT Japan, and by a Joint Research Grant from the Institute of Science and Engineering, Chuo University. The authors acknowledge Mr. Katsunori Maejima, Chuo University, for skillful experiments related to Hb purification, Dr. Keitaro Sou, Waseda University, for his kind support on viscosity measurements, Dr. Yuichiro Hayashi, Keio University, for valuable comments related to histopathologic observations, and the members of the Radioisotope Center, Kumamoto University, for important contributions to pharmacokinetic experiments.

PY - 2015/7/29

Y1 - 2015/7/29

N2 - A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

AB - A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

UR - http://www.scopus.com/inward/record.url?scp=84938152957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938152957&partnerID=8YFLogxK

U2 - 10.1038/srep12778

DO - 10.1038/srep12778

M3 - Article

C2 - 26220366

AN - SCOPUS:84938152957

SN - 2045-2322

VL - 5

JO - Scientific Reports

JF - Scientific Reports

M1 - 12778

ER -

Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

抄録

ASJC Scopus subject areas

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル